Drugs / SAM-LNP-S-TCE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04776317 | Mar 2021 → Sep 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAM-LNP-S-TCE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04776317 ↗ |
| Known as | SAM-S-TCE | “Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector” NCT04776317 ↗ |
| Modality | Messenger RNA (mRNA) | “Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector” NCT04776317 ↗ |
| Route | Intramuscular | “A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle.” NCT04776317 ↗ |